Stock listing
BIVA:CABA Cabaletta Bio, Inc. Acciones
Mexican listing (BIVA) of Cabaletta Bio, Inc. · home listing NASDAQ:CABA
Follow Cabaletta Bio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CABA
$0.936 USD -0.119 (-11.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CABA
- Day range
- $0.930 – $1.030 USDNov 20, 2026
- Volume
- 3.73M sharesNov 20, 2026
- Market cap
- $201.9M USDAt the close on Nov 20, 2026 · price × 215.7M shares outstanding
- 52-week range
- $0.930 – $4.230 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $11.03M USDMedian day 5.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CABA · Home | $0.936 USD | -0.119 (-11.3%) | 3,730,726 | $0.990 | $1.030 | $0.930 | $1.055 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CABA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.936 | -0.119 | -11.3% | $0.990 | $1.030 | $0.930 | 3,730,726 | |
| $1.055 | +0.035 | +3.4% | $1.040 | $1.120 | $1.035 | 4,133,935 | |
| $1.020 | -0.090 | -8.1% | $1.090 | $1.160 | $0.982 | 5,455,620 | |
| $1.110 | -0.170 | -13.3% | $1.250 | $1.250 | $1.100 | 5,234,740 | |
| $1.280 | -0.050 | -3.8% | $1.340 | $1.350 | $1.250 | 3,217,950 | |
| $1.330 | -0.120 | -8.3% | $1.430 | $1.460 | $1.330 | 3,731,150 | |
| $1.450 | 0.000 | 0.0% | $1.460 | $1.520 | $1.375 | 3,763,705 | |
| $1.450 | -0.050 | -3.3% | $1.480 | $1.537 | $1.410 | 3,601,225 | |
| $1.500 | +0.200 | +15.4% | $1.370 | $1.550 | $1.370 | 8,165,908 | |
| $1.300 | +0.020 | +1.6% | $1.270 | $1.330 | $1.250 | 2,997,368 | |
| $1.280 | -0.140 | -9.9% | $1.410 | $1.430 | $1.180 | 6,245,584 | |
| $1.420 | 0.000 | 0.0% | $1.498 | $1.520 | $1.400 | 3,156,536 | |
| $1.420 | -0.010 | -0.7% | $1.430 | $1.495 | $1.400 | 2,857,405 | |
| $1.430 | -0.080 | -5.3% | $1.520 | $1.540 | $1.380 | 5,685,540 | |
| $1.510 | -0.075 | -4.7% | $1.540 | $1.585 | $1.430 | 3,727,617 | |
| $1.585 | +0.065 | +4.3% | $1.540 | $1.630 | $1.540 | 5,382,972 | |
| $1.520 | +0.065 | +4.5% | $1.440 | $1.530 | $1.420 | 5,829,617 | |
| $1.455 | +0.105 | +7.8% | $1.350 | $1.455 | $1.320 | 6,630,771 | |
| $1.350 | -0.120 | -8.2% | $1.460 | $1.470 | $1.320 | 6,235,769 | |
| $1.470 | -0.050 | -3.3% | $1.500 | $1.500 | $1.390 | 3,991,692 | |
| $1.520 | -0.020 | -1.3% | $1.530 | $1.555 | $1.485 | 2,240,356 | |
| $1.540 | -0.070 | -4.3% | $1.610 | $1.635 | $1.510 | 3,046,305 | |
| $1.610 | +0.130 | +8.8% | $1.513 | $1.630 | $1.450 | 3,462,663 | |
| $1.480 | +0.070 | +5.0% | $1.425 | $1.500 | $1.390 | 4,556,472 | |
| $1.410 | -0.140 | -9.0% | $1.560 | $1.620 | $1.400 | 6,674,200 | |
| $1.550 | -0.070 | -4.3% | $1.610 | $1.625 | $1.520 | 6,741,600 | |
| $1.620 | -0.070 | -4.1% | $1.640 | $1.680 | $1.505 | 6,235,700 | |
| $1.690 | -0.100 | -5.6% | $1.790 | $1.820 | $1.590 | 7,935,400 | |
| $1.790 | -0.140 | -7.3% | $1.940 | $1.940 | $1.780 | 4,830,000 | |
| $1.930 | -0.020 | -1.0% | $1.940 | $1.980 | $1.900 | 2,592,700 | |
| $1.950 | -0.020 | -1.0% | $1.960 | $1.970 | $1.870 | 5,942,300 | |
| $1.970 | -0.050 | -2.5% | $1.980 | $2.060 | $1.941 | 2,141,800 | |
| $2.020 | -0.060 | -2.9% | $2.100 | $2.138 | $1.960 | 4,127,200 | |
| $2.080 | +0.080 | +4.0% | $2.010 | $2.120 | $1.955 | 5,407,200 | |
| $2.000 | +0.110 | +5.8% | $1.940 | $2.010 | $1.830 | 5,705,700 | |
| $1.890 | -0.030 | -1.6% | $1.920 | $1.970 | $1.860 | 8,533,800 | |
| $1.920 | -0.060 | -3.0% | $2.010 | $2.010 | $1.900 | 8,051,400 | |
| $1.980 | -0.020 | -1.0% | $2.010 | $2.030 | $1.950 | 4,192,200 | |
| $2.000 | -0.070 | -3.4% | $2.060 | $2.070 | $1.980 | 5,436,200 | |
| $2.070 | -0.085 | -3.9% | $2.170 | $2.170 | $2.050 | 3,096,200 | |
| $2.155 | -0.065 | -2.9% | $2.230 | $2.230 | $2.060 | 5,589,900 | |
| $2.220 | -0.280 | -11.2% | $2.530 | $2.560 | $2.190 | 8,671,600 | |
| $2.500 | +0.040 | +1.6% | $2.480 | $2.600 | $2.460 | 5,312,900 | |
| $2.460 | -0.090 | -3.5% | $2.640 | $2.650 | $2.450 | 4,725,700 | |
| $2.550 | -0.030 | -1.2% | $2.550 | $2.610 | $2.520 | 12,483,700 | |
| $2.580 | +0.090 | +3.6% | $2.520 | $2.590 | $2.500 | 4,258,000 | |
| $2.490 | -0.105 | -4.0% | $2.650 | $2.680 | $2.480 | 6,141,000 | |
| $2.595 | -0.315 | -10.8% | $2.890 | $2.920 | $2.570 | 7,233,600 | |
| $2.910 | +0.180 | +6.6% | $2.720 | $3.040 | $2.710 | 6,311,000 | |
| $2.730 | -0.010 | -0.4% | $2.770 | $2.886 | $2.670 | 7,434,600 | |
| $2.740 | -0.170 | -5.8% | $2.850 | $2.875 | $2.690 | 7,077,200 | |
| $2.910 | -0.360 | -11.0% | $3.280 | $3.280 | $2.900 | 6,511,000 | |
| $3.270 | -0.200 | -5.8% | $3.430 | $3.480 | $3.260 | 3,062,900 | |
| $3.470 | -0.010 | -0.3% | $3.460 | $3.600 | $3.400 | 4,893,100 | |
| $3.480 | -0.090 | -2.5% | $3.630 | $3.750 | $3.470 | 7,437,000 | |
| $3.570 | +0.270 | +8.2% | $3.270 | $3.580 | $3.250 | 8,042,800 | |
| $3.300 | +0.190 | +6.1% | $3.000 | $3.315 | $2.840 | 6,645,700 | |
| $3.110 | -0.010 | -0.3% | $3.105 | $3.205 | $3.080 | 3,024,500 | |
| $3.120 | -0.260 | -7.7% | $3.360 | $3.375 | $3.110 | 3,234,200 | |
| $3.380 | +0.130 | +4.0% | $3.240 | $3.445 | $3.230 | 3,800,400 | |
| $3.250 | +0.030 | +0.9% | $3.200 | $3.270 | $3.170 | 2,484,400 | |
| $3.220 | +0.120 | +3.9% | $3.140 | $3.279 | $3.110 | 3,970,737 | |
| $3.100 | -0.030 | -1.0% | $3.090 | $3.170 | $3.010 | 3,107,920 | |
| $3.130 | -0.060 | -1.9% | $3.200 | $3.340 | $3.085 | 4,402,300 | |
| $3.190 | +0.090 | +2.9% | $3.040 | $3.240 | $2.950 | 5,738,100 |
- Ticker
- BIVA:CABA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BIVA
- Currency
- MXN
What changed lately
Latest news release · Nov 8, 2026
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 48 slides
Latest news
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Nov 8, 2026
Closed $1.50 (+15.4%) on Nov 9, 2026
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $1.28 (-9.9%) on Nov 5, 2026
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2026
Closed $1.28 (-9.9%) on Nov 5, 2026
Cabaletta Bio to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $1.42 (-0.7%) on Nov 3, 2026
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $2.71 (-4.9%) on Aug 13, 2026
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Jun 3, 2026
Closed $3.58 (-2.7%) on Jun 3, 2026
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed $3.61 (+0.6%) on May 14, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 4, 2026
Closed $3.83 (+30.3%) on May 4, 2026
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Apr 28, 2026
Closed $2.86 (-1.7%) on Apr 28, 2026
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Apr 28, 2026
Closed $2.86 (-1.7%) on Apr 28, 2026
Cabaletta Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 126 in all · newest Nov 8, 2026 · oldest 2019
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 20, 2024
- Decks
- 51 decks · latest Nov 9, 2026
Where Cabaletta Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CABA · Home listing | NASDAQ | United States | USD |
| BOATS:CABA | BOATS | United States | USD |
| BMV:CABA | BMV | Mexico | MXN |
| BIVA:CABA · This page | BIVA | Mexico | MXN |
Valuation
Price/book 0.7× against a median of 6.0×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$97.45M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cabaletta Bio, Inc. · NASDAQ:CABA | US$201.9M | −US$97.45M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.89 |
| AnnJi Pharmaceutical Co., Ltd. · TPEX:7754 | US$209.9M | US$196.0M | n/a | 855× | n/a | 16.5× | n/a | 0.0× | n/a |
| Racura Oncology Ltd · ASX:RAC | US$207.6M | US$184.9M | n/a | n/a | n/a | 8.6× | n/a | 0.0× | n/a |
| Hightide Therapeutics Inc · HKEX:2511 | US$204.6M | US$178.8M | n/a | n/a | n/a | 8.2× | n/a | 0.9× | n/a |
| PharmaEngine, Inc. · TPEX:4162 | US$204.2M | US$50.36M | 12.5× | 1.6× | 3.4× | 1.4× | 52.6% | 0.0× | n/a |
| Bright Minds Biosciences Inc. · CSE:DRUG | US$199.5M | −US$15.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.32 |
| Newron Pharmaceuticals S.p.A. · SIX:NWRN | US$199.5M | US$206.2M | n/a | 9.8× | n/a | n/a | −69.2% | n/a | n/a |
| NervGen Pharma Corp. · NASDAQ:NGEN | US$198.4M | US$137.8M | n/a | n/a | n/a | 16.4× | n/a | 0.0× | 1.46 |
| BioAge Labs, Inc. · NASDAQ:BIOA | US$196.4M | −US$87.20M | n/a | −10.1× | n/a | 0.6× | n/a | 0.0× | 2.06 |
| Lineage Cell Therapeutics, Inc. · AMEX:LCTX | US$195.3M | US$152.1M | 111× | 14.0× | n/a | 2.9× | 16.2% | 0.0× | 1.33 |
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| Median of the others | US$199.5M | US$144.9M | 61.9× | 7.3× | 3.4× | 6.0× | −26.5% | 0.0× | 1.46 |
Forecasts
7 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.29 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Steven Nichtberger | President, Chief Executive Officer, and Co-Founder |
| Anup Marda | Chief Financial Officer |
| Richard Henriques | Independent Director, former CFO of Gates Foundation, former Controller at Merck |
| Gwendolyn Binder | President, Science & Technology |
| Michael Gerard | General Counsel |
| Arun Das | Chief Business Officer |
| David J. Chang | Chief Medical Officer |
| Heather Harte-Hall | Chief Compliance Officer |
| Nicolette Sherman | Chief Human Resources Officer |
| Samik Basu | Chief Scientific Officer |
| Sarah Yuan | Chief Technology Officer |
| Steve Gavel | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Catherine Bollard | Independent Director, George Washington University |
| Mark Simon | Independent Director, Torreya Partners |
| Richard Henriques | Independent Director, former CFO of Gates Foundation, former Controller at Merck |
| Scott Brun | Independent Director, formerly at AbbVie |
| Shawn Tomasello | Independent Director, former CCO of Kite Pharma, Inc. |
| Steven Nichtberger | President, Chief Executive Officer, and Co-Founder |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cabaletta Bio (NASDAQ:CABA) Q3 2024 Earnings Call | Wed, Nov 20, 2024 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −9.9% |
| Q2 2026 | Aug 13, 2026 · Before open | −4.9% |
| Q1 2026 | May 14, 2026 · Before open | +0.6% |
| Q4 2025 | Mar 12, 2026 | −6.4% |
| Q3 2025 | Nov 10, 2025 · Before open | −4.7% |
| Q2 2025 | Aug 7, 2025 · Before open | 0.0% |
| Q1 2025 | May 15, 2025 · Before open | +39.2% |
| Q4 2024 | Mar 19, 2025 · Before open | +6.6% |
| Q3 2024 | Nov 14, 2024 · Before open | −5.7% |
| Q2 2024 | Aug 8, 2024 · Before open | −34.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | +13.0% |
| Q4 2023 | Mar 21, 2024 · Before open | −3.2% |
| Q3 2023 | Nov 9, 2023 · Before open | +1.9% |
| Q2 2023 | Aug 10, 2023 · Before open | −0.9% |
| Q1 2023 | May 11, 2023 · Before open | +6.7% |
| Q4 2022 | Mar 16, 2023 · Before open | +4.6% |
| Q3 2022 | Nov 10, 2022 · Before open | +4.6% |
| Q2 2022 | Aug 11, 2022 · Before open | +13.3% |
| Q1 2022 | May 12, 2022 · Before open | +7.3% |
| Q4 2021 | Mar 17, 2022 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 48 slides | Nov 9, 2026 |
| Investor Presentation (September 2026) | Investor deck | 50 slides | September 2026 |
| Investor Presentation (June 2026) | Investor deck | 51 slides | Jun 3, 2026 |
| Investor Presentation (May 2026) | Investor deck | 50 slides | May 14, 2026 |
| Investor Presentation (May 2026) | Investor deck | 51 slides | May 4, 2026 |
| Investor Presentation (April 2026) | Investor deck | 50 slides | Apr 20, 2026 |
| Investor Presentation (March 2026) | Investor deck | 48 slides | Mar 23, 2026 |
| Investor Presentation (January 2026) | Investor deck | 48 slides | Jan 12, 2026 |
| Investor Presentation (October 2025) | Investor deck | 52 slides | Oct 29, 2025 |
| Investor Presentation (October 2025) | Investor deck | 49 slides | Oct 27, 2025 |
Show 50 decks
This page holds 50 of 51 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$150M · US$2.9 a share · TD Cowen +3 Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), H.C. Wainwright & Co. Buyers: Bain Capital Life Sciences; Adage Capital Management; Cormorant Asset Management; Eli Lilly and Company | May 4, 2026 |
| Public offering of common stock and accompanying warrants (or pre-funded warrants in lieu thereof) Update: about US$100M · US$2 a share · 1 warrant at US$2.5 for 15 months · Jefferies +2 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Cantor (co-lead) | Jun 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$11.00 a share on Oct 24, 2019.
- Price
- US$11.00 a share
- Shares offered
- 6,800,000 shares of common stock
- Offering size
- US$74.8 million
- Underwriters' option
- Up to 1,020,000 more shares
- Underwriters
- MORGAN STANLEY, COWEN, EVERCORE ISI · In the order on the cover
- Shares delivered
- On or about Oct 29, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 2, 2019 |
| Filed publicly | Sep 30, 2019 |
| Amended once | Oct 16, 2019 |
| Shares registered with an exchange | Oct 23, 2019 |
| Declared effective by the SEC | Oct 24, 2019 |
| Final prospectus, with the price | Oct 25, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 25, 2019 |
| EFFECT · Notice that a registration is effective | Oct 24, 2019 |
| S-1MEF · Registration of more shares for the same offering | Oct 24, 2019 |
| CERT · Exchange's certificate of listing | Oct 24, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 23, 2019 |
| CORRESP · Letter to the SEC | Oct 22, 2019 |
| CORRESP · Letter to the SEC | Oct 22, 2019 |
| S-1/A · Registration statement, amended | Oct 16, 2019 |
| CORRESP · Letter to the SEC | Oct 11, 2019 |
| CORRESP · Letter to the SEC | Oct 9, 2019 |
All 19 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 30, 2019 |
| S-1 · Registration statement | Sep 30, 2019 |
| DRSLTR · Letter to the SEC with a draft | Sep 20, 2019 |
| DRS/A · Draft registration statement, amended | Sep 20, 2019 |
| UPLOAD · Letter from the SEC | Sep 18, 2019 |
| DRSLTR · Letter to the SEC with a draft | Sep 6, 2019 |
| DRS/A · Draft registration statement, amended | Sep 6, 2019 |
| UPLOAD · Letter from the SEC | Aug 28, 2019 |
| DRS · Draft registration statement | Aug 2, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 25, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 142.7M | 97.2M | 55.4M | 39.3M | 32.5M | 21.4M | 11.7M | 4.47M |
| Operating income | -172.2M | -125.1M | -74.7M | -54.1M | -46.3M | -33.8M | -18.7M | -6.19M |
| Depreciation and amortization | 1.65M | 1.71M | 1.43M | 1.18M | 733.0K | 354.0K | 104.0K | 0 |
| EBITDA | -170.6M | -123.4M | -73.2M | -53.0M | -45.6M | -33.5M | -18.6M | -6.19M |
| Interest expense | 2.00M | 748.0K | 0 | |||||
| Income tax | 0 | 0 | ||||||
| Net income | -167.9M | -115.9M | -67.7M | -53.0M | -46.3M | -33.3M | -16.9M | -12.2M |
| Earnings per share, basic | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 | -1.44 | -4.07 | -6.87 |
| Earnings per share, diluted | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 | -1.44 | -4.07 | -6.87 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 83.0M | 164.0M | 193.2M | 81.6M | 122.2M | 101.4M | 136.2M | 33.0M |
| Short-term investments | 50.6M | 0 | 48.0M | 24.9M | 0 | 7.23M | ||
| Current assets | 138.9M | 166.7M | 244.5M | 108.8M | 124.5M | 113.5M | 140.6M | 34.0M |
| Property, plant and equipment | 1.92M | 2.74M | 2.54M | 2.58M | 1.44M | 890.0K | 815.0K | |
| Total assets | 165.1M | 185.0M | 253.7M | 117.0M | 126.3M | 114.7M | 141.5M | 34.2M |
| Accounts payable | 6.64M | 4.92M | 4.55M | 2.46M | 2.33M | 1.24M | 920.0K | 603.0K |
| Current liabilities | 50.2M | 27.1M | 16.0M | 9.49M | 8.38M | 5.18M | 3.15M | 943.0K |
| Total liabilities | 53.0M | 32.7M | 17.5M | 12.4M | 8.38M | |||
| Shareholders' equity | 112.1M | 152.3M | 236.2M | 104.5M | 118.0M | 109.5M | 138.3M | -10.7M |
| Shares outstanding | 100.5M | 50.7M | 47.8M | 29.4M | 28.9M | 24.1M | 24.0M | 3.85M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -131.1M | -88.2M | -53.5M | -46.4M | -34.1M | -26.8M | -16.0M | -4.66M |
| Capital spending | -1.23M | -2.21M | -687.0K | -2.45M | -1.17M | -635.0K | -693.0K | |
| Free cash flow | -132.3M | -90.4M | -54.2M | -48.8M | -35.3M | -27.4M | -16.7M | |
| Cash from investing | -50.3M | 47.3M | -22.5M | -27.2M | 6.00M | -7.98M | -693.0K | |
| Cash from financing | 100.3M | 11.7M | 187.6M | 33.0M | 48.9M | -24.0K | 119.9M | 37.7M |
| Change in cash | -81.0M | -29.3M | 111.6M | -40.6M | 20.8M | -34.8M | 103.2M | 33.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 1, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| 424B5 · Prospectus | May 4, 2026 | Offer document | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| ARS · Annual report to shareholders | May 13, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 13, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| POSASR | Mar 31, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Feb 18, 2025 | Current report | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 8-K · Current report | Sep 30, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Aug 22, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jun 10, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| S-3ASR · Registration statement | Mar 21, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 21, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 8-K · Current report | Mar 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 1, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
This page holds 200 of 454 filings. Open Filings
Cap table
Built by 6ix from Cabaletta Bio, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 215,720,392
- Fully diluted
- 215,720,392
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 215,720,392 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 215,720,392 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shawn Tomasello Other companies: 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); UroGen Pharma Ltd. (Director · Jun 7, 2021 – Jun 7, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past) | Director · Since at least Jul 21, 2023 |
| Brian Daniels Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Bristol-Myers Squibb Company (SVP Global Dev & Med Affairs · Mar 4, 2008 – Jul 1, 2014 · Past) | Director · Oct 24, 2019 – Jun 1, 2021 · Past |
| Scott Brun Other companies: Jasper Therapeutics, Inc. (Director · Since at least Jun 20, 2023); Forte Biosciences, Inc. (Director · Since at least Nov 10, 2022) | Independent Director, formerly at AbbVie · Since at least Jun 24, 2021 |
| Gwendolyn Binder Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021) | President, Science & Technology · Since at least Oct 24, 2019 |
| Richard C Henriques Jr Other companies: Arbutus Biopharma Corporation (Director · Dec 31, 2014 – May 23, 2024 · Past) | Director · Since at least Oct 24, 2019 |
| Anup Marda | Chief Financial Officer · Since at least Oct 24, 2019 |
| Arun Das | Chief Business Officer · Since at least Jan 5, 2022 |
| Catherine Bollard | Independent Director, George Washington University · Since at least Nov 5, 2026 |
| David J. Chang | Chief Medical Officer · Since at least Oct 24, 2019 |
| Heather Harte-Hall | Chief Compliance Officer · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| John Brian Stalter | General Counsel · Oct 24, 2019 – Mar 1, 2021 · Past |
| Mark Simon | Director · Since at least Jun 3, 2024 |
| Michael Gerard | General Counsel · Since at least Sep 1, 2021 |
| Nicolette Sherman | Chief Human Resources Officer · Since at least Nov 14, 2024 |
| Richard Henriques | Independent Director, former CFO of Gates Foundation, former Controller at Merck · Since at least Nov 5, 2026 |
| Samik Basu | Chief Scientific Officer · Since at least Oct 9, 2025 |
| Sarah Yuan | Chief Technology Officer · Since at least Nov 5, 2026 |
| Steve Gavel | Chief Commercial Officer · Since at least Oct 14, 2025 |
| Steven Nichtberger | President, Chief Executive Officer, and Co-Founder · Since at least Aug 13, 2026 |
| Steven Nichtberger | President & CEO, Director · Since at least Oct 24, 2019 |
Log in to ask 6ix AI your own questions about Cabaletta Bio, Inc.